The effect of haloperidol on epinephrine-stimulated adenylate cyclase in humans.
Administration of epinephrine in man has been shown previously to lead to a rise in plasma cyclic AMP levels by activation of the beta-adrenergic-stimulated adenylate cyclase. Therapeutic doses of lithium in humans block the epinephrine-induced rise in plasma cyclic AMP levels, suggesting that lithium inhibits beta-adrenergic adenylate cyclase. In contrast, ten subjects receiving haloperidol, a druh also effective in the treatment of mania, show a mean rise in plasma cyclic AMP levels after epinephrine administration and the magnitude of the response is the same as for non-drug treated individuals. These findings are discussed in relation to the possible pharmacological mechanisms of action of lithium and haloperidol in the control of mania.
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000328:Adult; D001921:Brain / Q000201:enzymology; D000242:Cyclic AMP / Q000097:blood; D004837:Epinephrine / Q000494:pharmacology*; D005260:Female; D006220:Haloperidol / Q000494:pharmacology*; D006801:Humans; D008094:Lithium / Q000494:pharmacology; D008297:Male; D008875:Middle Aged
D008094:Lithium; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D006220:Haloperidol; D004837:Epinephrine